CSI Market
Sign In | Register

Kiromic Biopharma Inc (KRBP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KRBP Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Kiromic Biopharma Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Sep 30 2024) (Jun 30 2024) (Mar 31 2024) (Dec 31 2023)
Operating Activities
Income-26.90
Depreciation & amortization2.23
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventory Write-down0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.60
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest3.78
Increase Decrease In Deferred Rent-
Stock Issued-
Operating Lease Expense-
Gain Loss Related To Litigation Settlement Net Of Cash Payments-
Increase Decrease In Operating Lease Liability-0.47
Increase Decrease In Litigation Liability-
Notes Issued1.24
Debt Conversion Converted Instrument Amount-
Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Capital Expenditures Incurred But Not Yet Paid-
Write Off Of Deferred Debt Issuance Cost-
Operating Lease Right Of Use Asset Amortization Expense-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.54
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.57
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.28
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.24
Discontinued operations0.00
Net Cash flow from Operating Activities-19.46
Investing Activities
Capital Expenditures-0.37
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.37
Financing Activities
Short-term debt Net0.90
Other borrowing transactions0.00
Long-term debt - borrowings18.00
Long-term debt - repayments-0.49
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Loan Payable-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities18.42
Effect of exchange rate on cash flow-1.41
Discontinued operations0.00
Free Cash Flow-19.82
Total Cash Flow-2.82
4 historic quarters locked

Sign in to unlock the full Kiromic Biopharma Inc cash flow history.

Sign In Create Free Account

About Kiromic Biopharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-24-034182

Figures are derived from filed reports and may be restated. Historical data is subject to revision.